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In this issue of Blood, Bernardo et al demonstrate that monoclonal antibody combinations recapitulate the efficacy of polyclonal antibodies in suppressing red blood cell (RBC) alloimmunization. These results hold significant promise in the development of monoclonal antibody alternatives to human-derived sources for anti-Rh (RhD) immunoprophylaxis. 1 T he discovery of ABO(H) blood group antigens resulted in the birth of transfusion medicine and allowed for the first time the use of a laboratory test that could predict immunologic outcomes prior to transfusion. Although ABO(H) antibody testing continues to represent one of the first and most common examples of personalized medicine, it was not until many years later that the existence of non-ABO(H) blood group antigens relevant in transfusion became apparent. One of the earliest descriptions of a non-ABO(H) reaction occurred following a hemolytic transfusion in the mother of a stillborn child following infusion of otherwise ABO(H)-compatible blood donated by the father. 2 Additional investigation demonstrated that nearly 20% of individuals fail to express the Rh factor, a non-ABO(H) antigen also targeted on rhesus macaque RBCs following injection into rabbits. 3 Ensuing studies confirmed that the presence or absence of Rh factor directly correlated with the majority of ABO(H)-compatible transfusion reactions. 4 Subsequent reports demonstrated that the development of anti-Rh (RhD) antibodies might not only be responsible for ABO(H)-independent transfusion reactions, but may similarly underlie the development of hemolytic disease of the fetus and newborn (HDFN). 9 For .20 years, these studies exemplified the power of a multidisciplinary approach when seeking to not only understand but also develop a strategy to prevent a devastating disease. Although anti-RhD immunoprophylaxis continues to enjoy considerable success, several key drawbacks still exist. As the efficacy of RhD immunoprophylaxis reduced the incidence of RhD alloimmunization, the natural source of anti-RhD generated during pregnancy likewise decreased. As a result, manufacturing centers enrolled RhD-negative men and intentionally immunized these individuals figure) . These studies hold significant promise, as these findings suggest that blends of different monoclonal antibodies may provide a satisfactory substitute for the use of polyclonal preparations in the future. Equally important, although anti-RhD antibodies currently prevent antibody formation against RhD antigens, similar approaches do not exist for other RBC alloantigens. Indeed, in the wake of RhD immunoprophylaxis, anti-KEL antibodies are now responsible for more HDFN-related mortality than any other anti-RBC alloantibody. As a result, the present study not only holds promise in the potential development of monoclonal combinations that may replace naturally derived sources for anti-RhD, but may also serve as a platform to provide similar approaches to prevent equally devastating consequences of alloimmunization against other RBC alloantigens. As new models and mechanisms of antibody-mediated immunosuppresion become available, studies like these will continue to build on the successful history of RhD immunoprophylaxis to generate better products and thus extend this therapy to patients who continue to suffer from HDFN.
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In this issue of Blood, the groups of Louissaint et al 1 and Schmidt et al 2 report on the genetic landscape of pediatric-type follicular lymphoma (PTFL). Their studies confirm suspicions that PTFL represents a biologically distinct form of lymphoma, with fewer recurrent genetic alterations than typical FL. Because this group of patients has an excellent prognosis, accurate and reliable identification of PTFL is important to minimize the prospect of unnecessary treatment. Unfortunately, monoclonal anti-RBC antibodies often fail to completely prevent RBC alloantibody formation. However, by combining 2 monoclonal antibodies that target distinct alloantigen epitopes, a monoclonal antibody cocktail can be generated with the same ability to prevent RBC alloimmunization as polyclonal antibody preparations. Ab, antibody; 1, antibody formation; 2, no antibody formation.
